# Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct05417594/  
OnCo record `nct05417594` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Palacaparib, Temozolomide, Trastuzumab, Trastuzumab deruxtecan and Datopotamab deruxtecan in advanced solid tumours, run by AstraZeneca, now recruiting.

## Summary

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies. ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 695 participants. Primary completion is estimated at 2028-02-07. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AZD9574, Temozolomide (TMZ), [11C]AZ1419 3391, Trastuzumab Deruxtecan (T-DXd), Datopotamab Deruxtecan (Dato-DXd). Registered primary measures: Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs); Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs; Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-10-06
- Also known as: CERTIS1
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05417594
- Phase: 1/2
- Setting: Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Sponsor: AstraZeneca
- Enrolled: 695

## Notes

- ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 695 participants. Primary completion is estimated at 2028-02-07. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications.

## Sources

- ClinicalTrials.gov NCT05417594: https://clinicaltrials.gov/study/NCT05417594

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [TROP2](https://onco.cc/targets/trop2/)
- drugs: [Datopotamab deruxtecan](https://onco.cc/drugs/datopotamab-deruxtecan/), [Palacaparib](https://onco.cc/drugs/palacaparib/), [Temozolomide](https://onco.cc/drugs/temozolomide/), [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- institutions: [UCSF Helen Diller Family Comprehensive Cancer Center](https://onco.cc/institutions/ucsf/)

---
JSON: https://onco.cc/api/v1/entities/nct05417594.json